ARTICLE | Clinical News
MM-121: Phase II started
July 26, 2010 7:00 AM UTC
Merrimack began a double-blind, placebo-controlled, U.S. Phase II trial in about 130 patients to compare MM-121 plus Aromasin exemestane vs. Aromasin alone. sanofi-aventis has an exclusive, worldwide...